Browsing: Celltrion

Celltrion (068270.KS) is set to unveil preclinical results for its next-generation obesity treatment and early clinical data for antibody-drug conjugate (ADC) candidates in succession, bringing its new drug development progress into full view. The company aims to cultivate new drugs as a fresh growth pillar, drawing on the cash-generating power and research, development and commercialization…